1Chinese Society of Hepatology and Chinese Society of Infectious Diseases,Chinese Medical Association. 42 Dongsi Xidajie,Beijing 100710,China.慢性乙型肝炎防治指南[J].中华肝脏病杂志,2005,13(12):881-891. 被引量：1931
5Liaw YF,Leung N,Kao JH,et al.Asian-Pacific consensus statement on the management of chronic hepatitis B:a 2008 update.Hepatol Int,2008,2:263-283.
6Locarnini S.Primary resistance,multidrug resistance,and crossresistance pathways in HBV as a consequence of treatment failure.Hepatol Int,2008,2:147-151.
7European Association For The Study Of The Liver.EASL Clinical Practice Guidelines:management of chronic hepatitis B.J Hepatol,2009,50:227-242.
8Liu F,Yu DM,Chen L,et al.Dynamic changes of hepatitis B virus quasispecies during early entecavir treatment in patients with different responses.APASL,2010:421.
9Tenney DJ,Rose RE,Baldick CJ,et al.Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-na(i)ve patients is rare through 5 years of therapy.Hepatology,2009,49:1503-1514.
10Carey I,Mendes A,Hughes S,et al.Efficacy and safety of Lamivudine plus Adefovir de novo combination therapy and Entecavir monotherapy in chronic Hepatitis B:A single centre clinical practice experience.2009,AASLD,502A.
